Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7 billion
INDIANAPOLIS: Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly will pay $3.25 billion upfront, with remaining payments contingent on clinical, regulatory and commercial milestones. The transaction is expected to close in the second half of 2026. Kelonia is developing technology to reprogram…